This CME/CE program provides a comprehensive overview of the diagnosis, risk stratification, and management strategies of acute deep vein thrombosis (DVT) and pulmonary embolism (PE). There is an emphasis on care in the outpatient setting, and on new therapeutics that may shorten or even obviate the need for hospitalization. The expert faculty discuss clinical data on current therapeutic options, risk-adjusted duration of treatment, and venous thromboembolism (VTE) management in special patient populations.
Healthcare professionals who care for patients with venous thromboembolism, including primary care physicians, internists, family medicine physicians, emergency medicine physicians, PAs and other supporting clinicians
- Understand the science and management of VTE, including the identification of patients in the primary care and ED settings
- Review clinical data on current treatment options including anticoagulants that inhibit free and clot bound factor Xa
- Discuss appropriate durations of treatment for VTE, as well as risk-adjusted secondary prevention of VTE and patient education
- Understand appropriate risk stratification and clinical decision making in the management of VTE in special populations
I. Scientific Update on the VTE and the Identification and Management of Patients in the Primary Care Setting and the Emergency Department – Charles V. Pollack Jr., MD
II. Clinical Trial Review and Clinical Applications of Anticoagulants Used to Treat and Prevent Blood Clots – Scott S. Kaatz, DO
III. Risk-Adjusted Duration of Therapy for VTE – Alexander Cohen, MBBS, MSc, MD
IV. VTE Management in Special Patient Populations – Alexander Cohen, MBBS, MSc, MD
V. Patient and Caregiver Education to Optimize Adherence to VTE Treatment, Utilizing the Healthcare Team: Interactive Panel Discussion – All Faculty
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|Alexander (Ander) Cohen, MBBS, MSc, MD, FRACP, FESC||Consultant/Advisor: Alexion Pharmaceuticals, Inc.; Boehringer Ingelheim International GmbH; Bayer AG; Bristol-Myers Squibb Company; Daiichi Sankyo Europe GmbH; Janssen Global Services, LLC; Pfizer Inc.; Sanofi-Aventis LLC|
|Scott Kaatz, DO||Consultant/Advisor: Alexion Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals; Boston Scientific Corporation; Bristol-Myers Squibb Company; CSL Behring; Gilead Sciences, Inc.; Janssen Global Services, LLC; Novartis AG; Pfizer Inc.
Research/Grant Support: Bristol-Myers Squibb Company; Janssen Global Services, LLC
|Charles Pollack, MA, MD, FACEP, FAHA, FACC, FESC||Consultant/Advisor: AstraZeneca Pharmaceuticals; PhaseBio Pharmaceuticals, Inc.; eXIthera Pharmaceuticals; Idorsia Pharmaceuticals, Ltd.; Milestone Pharmaceuticals, Inc.; VERO Biotech|
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Chelsey Benedek and Nicole McMenamin state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by educational grants from the Bristol Myers Squibb and Pfizer Alliance.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and the Bristol Myers Squibb and Pfizer Alliance do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 80% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].